{"id":5656,"date":"2014-10-21T09:00:00","date_gmt":"2014-10-21T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/"},"modified":"2024-09-23T11:22:41","modified_gmt":"2024-09-23T11:22:41","slug":"nanotechnologie-als-basis-voor-t1d-vaccin","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/","title":{"rendered":"Nano technologie als basis voor T1D-vaccin"},"content":{"rendered":"<p>Selecta Bioscience, een Amerikaans bedrijf in biotechnologie, is al jaren bezig om nanodeeltjes te ontwikkelen die als immuuntherapie gebruikt kunnen worden in T1D. Breakthrough T1D financierde al eerder een gedeelte van dit onderzoek, maar zorgt nu samen met farmaceut Sanofi dat het onderzoek kan worden voortgezet.<\/p>\n<p>Nanodeeltjes zijn hele kleine deeltjes. Als de juiste deeltjes op de juiste manier met elkaar worden samengevoegd, kan o<span class=\"text_exposed_show\">p die manier een nieuw deeltje ontstaan wat mogelijk T1D kan voorkomen.<\/span><\/p>\n<div class=\"text_exposed_show\">\n<p>Het onderzoek van Selecta richtte zich tot nu toe op het vinden en samenvoegen van de juiste deeltjes. Het vervolgonderzoek, gefinancierd door Breakthrough T1D en Sanofi, richt zich op het testen van de nanotechnologie in muizen.<\/p>\n<p>Als deze nanotechnologie omgezet kan worden tot een werkend vaccin dan zouden kinderen bijvoorbeeld in plaats van een DTP-prik een DTP-1 prik kunnen krijgen. Hiermee zou voorkomen kunnen worden dat T1D zich ontwikkeld.<\/p>\n<p><a href=\"http:\/\/jdrf.org\/blog\/2014\/making-the-t1d-vaccine-a-reality\/\">Lees meer (Engelstalig)<\/a><\/p>\n<\/div>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Selecta Bioscience, een Amerikaans bedrijf in biotechnologie, is al jaren bezig om nanodeeltjes te ontwikkelen die als immuuntherapie gebruikt kunnen worden in T1D. Breakthrough T1D financierde al eerder een gedeelte van dit onderzoek, maar zorgt nu samen met farmaceut Sanofi dat het onderzoek kan worden voortgezet. Nanodeeltjes zijn hele kleine deeltjes. Als de juiste deeltjes [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5656","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nano technologie als basis voor T1D-vaccin - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nano technologie als basis voor T1D-vaccin - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Selecta Bioscience, een Amerikaans bedrijf in biotechnologie, is al jaren bezig om nanodeeltjes te ontwikkelen die als immuuntherapie gebruikt kunnen worden in T1D. Breakthrough T1D financierde al eerder een gedeelte van dit onderzoek, maar zorgt nu samen met farmaceut Sanofi dat het onderzoek kan worden voortgezet. Nanodeeltjes zijn hele kleine deeltjes. Als de juiste deeltjes [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-21T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:41+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Nano technologie als basis voor T1D-vaccin\",\"datePublished\":\"2014-10-21T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\"},\"wordCount\":160,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\",\"name\":\"Nano technologie als basis voor T1D-vaccin - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2014-10-21T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nano technologie als basis voor T1D-vaccin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nano technologie als basis voor T1D-vaccin - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/","og_locale":"nl_NL","og_type":"article","og_title":"Nano technologie als basis voor T1D-vaccin - Breakthrough T1D","og_description":"Selecta Bioscience, een Amerikaans bedrijf in biotechnologie, is al jaren bezig om nanodeeltjes te ontwikkelen die als immuuntherapie gebruikt kunnen worden in T1D. Breakthrough T1D financierde al eerder een gedeelte van dit onderzoek, maar zorgt nu samen met farmaceut Sanofi dat het onderzoek kan worden voortgezet. Nanodeeltjes zijn hele kleine deeltjes. Als de juiste deeltjes [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/","og_site_name":"Breakthrough T1D","article_published_time":"2014-10-21T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:41+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Nano technologie als basis voor T1D-vaccin","datePublished":"2014-10-21T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/"},"wordCount":160,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/","name":"Nano technologie als basis voor T1D-vaccin - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2014-10-21T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nanotechnologie-als-basis-voor-t1d-vaccin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Nano technologie als basis voor T1D-vaccin"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5656"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5656\/revisions"}],"predecessor-version":[{"id":7180,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5656\/revisions\/7180"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}